Dyne Therapeutics Net Income
| DYN Stock | USD 15.28 0.26 1.67% |
As of the 17th of February 2026, Dyne Therapeutics shows the Mean Deviation of 3.02, variance of 17.56, and Standard Deviation of 4.19. Dyne Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Dyne Therapeutics Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -365 M | -383.3 M | |
| Net Loss | -285.7 M | -271.4 M | |
| Net Loss | -151.3 M | -143.7 M | |
| Net Loss | (3.88) | (4.07) | |
| Net Income Per E B T | 1.14 | 0.74 |
Dyne | Net Income | Build AI portfolio with Dyne Stock |
Evaluating Dyne Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Dyne Therapeutics's fundamental strength.
Latest Dyne Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Dyne Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Dyne Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dyne Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Dyne Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dyne Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (317.42 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Dyne Net Income Regression Statistics
| Arithmetic Mean | (266,134,114) | |
| Coefficient Of Variation | (181.82) | |
| Mean Deviation | 318,814,853 | |
| Median | (149,291,000) | |
| Standard Deviation | 483,874,104 | |
| Sample Variance | 234134.1T | |
| Range | 1.9B | |
| R-Value | 0.08 | |
| Mean Square Error | 248030.4T | |
| R-Squared | 0.01 | |
| Significance | 0.75 | |
| Slope | 7,935,057 | |
| Total Sum of Squares | 3746146.4T |
Dyne Net Income History
Other Fundumenentals of Dyne Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Dyne Therapeutics Net Income component correlations
Dyne Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Dyne Therapeutics is extremely important. It helps to project a fair market value of Dyne Stock properly, considering its historical fundamentals such as Net Income. Since Dyne Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dyne Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dyne Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Dyne Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Dyne Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Dyne Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Dyne Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Dyne Therapeutics or generate 0.0% return on investment in Dyne Therapeutics over 90 days. Dyne Therapeutics is related to or competes with Ultragenyx, Soleno Therapeutics, Centessa Pharmaceuticals, Xenon Pharmaceuticals, Apogee Therapeutics, Ascentage Pharma, and Mirum Pharmaceuticals. Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therape... More
Dyne Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Dyne Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Dyne Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 26.4 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 7.01 |
Dyne Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dyne Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Dyne Therapeutics' standard deviation. In reality, there are many statistical measures that can use Dyne Therapeutics historical prices to predict the future Dyne Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | (0.62) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dyne Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dyne Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.61) | |||
| Mean Deviation | 3.02 | |||
| Coefficient Of Variation | (1,429) | |||
| Standard Deviation | 4.19 | |||
| Variance | 17.56 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | (0.62) | |||
| Maximum Drawdown | 26.4 | |||
| Value At Risk | (5.89) | |||
| Potential Upside | 7.01 | |||
| Skewness | (0.63) | |||
| Kurtosis | 3.09 |
Dyne Therapeutics Backtested Returns
Dyne Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0971, which denotes the company had a -0.0971 % return per unit of risk over the last 3 months. Dyne Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Dyne Therapeutics' Standard Deviation of 4.19, mean deviation of 3.02, and Variance of 17.56 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.49, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dyne Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dyne Therapeutics is expected to be smaller as well. At this point, Dyne Therapeutics has a negative expected return of -0.4%. Please make sure to confirm Dyne Therapeutics' information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Dyne Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.12 |
Insignificant predictability
Dyne Therapeutics has insignificant predictability. Overlapping area represents the amount of predictability between Dyne Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Dyne Therapeutics price movement. The serial correlation of 0.12 indicates that less than 12.0% of current Dyne Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.12 | |
| Spearman Rank Test | 0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.9 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Dyne Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Dyne Therapeutics reported net income of (317.42 Million). This is 193.01% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 155.59% higher than that of the company.
Dyne Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dyne Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dyne Therapeutics could also be used in its relative valuation, which is a method of valuing Dyne Therapeutics by comparing valuation metrics of similar companies.Dyne Therapeutics is currently under evaluation in net income category among its peers.
Dyne Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Dyne Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Dyne Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Dyne Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Dyne Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Dyne Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dyne Therapeutics' value.| Shares | Jpmorgan Chase & Co | 2025-06-30 | 3.1 M | Armistice Capital, Llc | 2025-06-30 | 2.6 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.4 M | Geode Capital Management, Llc | 2025-06-30 | 2.3 M | Perceptive Advisors Llc | 2025-06-30 | 2.2 M | Vr Adviser, Llc | 2025-06-30 | 2.2 M | Logos Global Management Lp | 2025-06-30 | 1.9 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 1.8 M | Rtw Investments, Llc | 2025-06-30 | 1.7 M | Ra Capital Management, Llc | 2025-06-30 | 9.7 M | Hhg Plc | 2025-06-30 | 9.4 M |
Dyne Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 1.89 B | ||||
| Shares Outstanding | 164.65 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 99.57 % | ||||
| Number Of Shares Shorted | 19.19 M | ||||
| Price To Earning | 35.58 X | ||||
| Price To Book | 3.70 X | ||||
| EBITDA | (315.18 M) | ||||
| Net Income | (317.42 M) | ||||
| Cash And Equivalents | 291.84 M | ||||
| Cash Per Share | 5.64 X | ||||
| Total Debt | 23.99 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.63 X | ||||
| Book Value Per Share | 4.85 X | ||||
| Cash Flow From Operations | (292.37 M) | ||||
| Short Ratio | 8.83 X | ||||
| Earnings Per Share | (3.62) X | ||||
| Price To Earnings To Growth | 0.19 X | ||||
| Target Price | 39.13 | ||||
| Number Of Employees | 240 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 2.52 B | ||||
| Total Asset | 691.23 M | ||||
| Retained Earnings | (949.93 M) | ||||
| Working Capital | 617.02 M | ||||
| Current Asset | 1.93 B | ||||
| Current Liabilities | 809 M | ||||
| Net Asset | 691.23 M |
About Dyne Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dyne Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Dyne Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Dyne Stock
Moving against Dyne Stock
| 0.82 | DRTS | Alpha Tau Medical | PairCorr |
| 0.71 | VALN | Valneva SE ADR | PairCorr |
| 0.69 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.66 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.65 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.